Your browser doesn't support javascript.
Cannabidiol for cannabis use disorder: too high hopes? - Authors' reply.
Freeman, Tom P; Hindocha, Chandni; Baio, Gianluca; Curran, H Valerie.
  • Freeman TP; Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath BA2 7AY, UK; Clinical Psychopharmacology Unit, University College London, London, UK; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University C
  • Hindocha C; Clinical Psychopharmacology Unit, University College London, London, UK; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, London, UK; National Institute for Health Research, University College London Hospit
  • Baio G; Department of Statistical Science, University College London, London, UK.
  • Curran HV; Clinical Psychopharmacology Unit, University College London, London, UK; National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK.
Lancet Psychiatry ; 7(10): 840, 2020 10.
Article in English | MEDLINE | ID: covidwho-807160
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cannabis / Hallucinogens Type of study: Prognostic study / Randomized controlled trials Language: English Journal: Lancet Psychiatry Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cannabis / Hallucinogens Type of study: Prognostic study / Randomized controlled trials Language: English Journal: Lancet Psychiatry Year: 2020 Document Type: Article